There is a disconnect in valuation for both companies in the same epigenetics space.  

Yes, I'm well aware of that.

My earlier response was on the price of the PPs:

Some folks think the PPs SHOULD be higher because the valuation SHOULD be higher and DM SHOULD be managing it better. And while we're at it, I SHOULD be dating Charlize Theron and I SHOULD win the lottery next week.  Great!  But that's not the current REALITY. The valuation IS what it IS.  ZHCLF is trading at 26¢.  THEREFORE, PPs at $1.50 look pretty good to me.

And sure, I'd like some questions answered at the AGM.

- what happened to the hints about near term $$$ in our pockets?
- is he entirely focussed on RVX and putting ZCC on auto pilot for the next 3-5 years?
- how and when does he see an exit for shareholders?

On the other hand, I'm not sure what point there is asking such questions.  Most folks (including me) won't believe much of what we hear.